Compare LWAY & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LWAY | SENS |
|---|---|---|
| Founded | 1986 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Industrial Machinery/Components |
| Sector | Consumer Staples | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.4M | 301.2M |
| IPO Year | 1995 | 2014 |
| Metric | LWAY | SENS |
|---|---|---|
| Price | $29.39 | $5.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $34.50 | $18.38 |
| AVG Volume (30 Days) | 142.1K | ★ 551.8K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.33 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $103,350,000.00 | $16,389,000.00 |
| Revenue This Year | $16.64 | $74.15 |
| Revenue Next Year | $17.28 | $58.60 |
| P/E Ratio | $101.10 | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $17.31 | $0.41 |
| 52 Week High | $34.20 | $8.75 |
| Indicator | LWAY | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 69.88 | 37.97 |
| Support Level | $22.03 | $5.40 |
| Resistance Level | $34.20 | $5.94 |
| Average True Range (ATR) | 1.35 | 0.46 |
| MACD | 0.66 | -0.21 |
| Stochastic Oscillator | 75.88 | 15.22 |
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir, which is a cultured dairy product. Its product categories are Drinkable Kefir, which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir, and Other dairy. The company manufactures and markets products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through a direct sales force, brokers, and distributors.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.